MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 75.40K | 65.70K | 48.40K | 54.50K | 71.80K |
| Gross Profit | -75.40K | -65.70K | -48.40K | -54.50K | -71.80K |
| SG&A Expenses | 174.10K | 96.90K | 86.90K | 96.70K | 163.20K |
| Depreciation & Amortization | 100.00 | 500.00 | 500.00 | 700.00 | 700.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 249.60K | 163.00K | 247.70K | 286.10K | 235.70K |
| Operating Income | -249.60K | -163.00K | -247.70K | -286.10K | -235.70K |
| Income Before Tax | -277.00K | -191.30K | -276.10K | 345.40K | -397.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -277.00K | -191.30K | -276.10K | 345.40K | -397.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -277.00K | -191.30K | -276.10K | 345.40K | -397.90K |
| EBIT | -249.60K | -163.00K | -247.70K | -286.10K | -235.70K |
| EBITDA | -249.50K | -162.60K | -247.20K | -285.50K | -235.00K |
| EPS Basic | -0.01 | 0.00 | -0.01 | 0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | 0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 46.27M | 46.27M | 47.05M | 47.94M | 47.05M |
| Average Diluted Shares Outstanding | 46.27M | 46.27M | 47.05M | 47.94M | 47.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |